Picture of CASI Pharmaceuticals logo

CASI CASI Pharmaceuticals Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Annual income statement for CASI Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K20-F
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue04.1315.130.243.1
Cost of Revenue
Gross Profit0.1965.6317.627.3
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses27.251.166.772.977.1
Operating Profit-27.2-47-51.5-42.7-34
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-27.5-45.4-47.5-35.8-37.4
Provision for Income Taxes
Net Income After Taxes-27.5-45.4-47.5-35.8-39.4
Minority Interest
Equity in Affiliates
Net Income Before Extraordinary Items
Net Income-27.5-45-46.6-35.1-31.5
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-27.5-46-48.3-36.7-41
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-3.16-4.03-2.72-2.15-2.49